{
    "Trade/Device Name(s)": [
        "AssureTech DOA Dipstick Screen Panel Tests",
        "AssureTech DOA Integrated Cup Tests"
    ],
    "Submitter Information": "Assure Tech. Co., Ltd.",
    "510(k) Number": "K201630",
    "Predicate Device Reference 510(k) Number(s)": [
        "K181768",
        "K182123"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG",
        "DKZ",
        "LDJ",
        "DIO",
        "LAF",
        "JXM",
        "DIS",
        "LCM",
        "DJR",
        "LFG",
        "JXN"
    ],
    "Summary Letter Date": "August 12, 2021",
    "Summary Letter Received Date": "September 30, 2020",
    "Submission Date": "September 29, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.3650",
        "21 CFR 862.3100",
        "21 CFR 862.3870",
        "21 CFR 862.3250",
        "21 CFR 862.3610",
        "21 CFR 862.3170",
        "21 CFR 862.3150",
        "21 CFR 862.3620",
        "21 CFR 862.3910",
        "21 CFR 862.3700"
    ],
    "Regulation Name(s)": [
        "Opiate Test System",
        "Amphetamine Test System",
        "Cannabinoids Test System",
        "Cocaine and Cocaine Metabolites Test System",
        "Methamphetamine Test System",
        "Benzodiazepine Test System",
        "Barbiturate Test System",
        "Methadone Test System",
        "Tricyclic Antidepressant Drugs Test System",
        "Propoxyphene Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "6-Monoacetylmorphine",
        "Amphetamine",
        "Oxazepam",
        "Cocaine",
        "Marijuana",
        "Methamphetamine",
        "Morphine",
        "Oxycodone",
        "Secobarbital",
        "Buprenorphine",
        "Methylenedioxy-methamphetamine",
        "Phencyclidine",
        "Methadone",
        "EDDP",
        "Nortriptyline",
        "d-Propoxyphene"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Urine cup"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Competitive binding",
        "Lateral flow immunochromatographic assay",
        "Antigen-antibody immunochemistry"
    ],
    "Methodologies": [
        "Immunochromatographic assay",
        "Lateral flow chromatographic immunoassay"
    ],
    "Submission Type(s)": [
        "Dipstick",
        "Panel",
        "Cup",
        "Test Device",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for AssureTech DOA Dipstick Screen Panel Tests and AssureTech DOA Integrated Cup Tests for qualitative detection of multiple drugs of abuse in human urine by lateral flow immunochromatographic assay",
    "Indications for Use Summary": "Qualitative and simultaneous detection of up to 16 drugs of abuse in human urine at specified cutoff concentrations, providing preliminary screening results for in vitro diagnostic use; confirmation with more specific analytical methods required.",
    "fda_folder": "Toxicology"
}